Works matching IS 11707690 AND DT 2021 AND VI 39 AND IP 3


Results: 8
    1
    2
    3
    4
    5
    6

    Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).

    Published in:
    PharmacoEconomics, 2021, v. 39, n. 3, p. 331, doi. 10.1007/s40273-020-00987-3
    By:
    • Bousmah, Marwân-al-Qays;
    • Nishimwe, Marie Libérée;
    • Tovar-Sanchez, Tamara;
    • Lantche Wandji, Martial;
    • Mpoudi-Etame, Mireille;
    • Maradan, Gwenaëlle;
    • Omgba Bassega, Pierrette;
    • Varloteaux, Marie;
    • Montoyo, Alice;
    • Kouanfack, Charles;
    • Delaporte, Eric;
    • Boyer, Sylvie;
    • For The New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group;
    • Ayouba, A.;
    • Agholeng, A.;
    • Butel, C.;
    • Cournil, A.;
    • Delaporte, E.;
    • Eymard-Duvernay, S.;
    • Granouillac, B.
    Publication type:
    Article
    7
    8